baasnmann
Results from a randomized Phase II study of 103 previously untreated patients with advanced pancreatic cancer demonstrated median overall survival with axitinib in combination with gemcitabine of 6.9 months compared with 5.6 months with gemcitabine alone. Axitinib combined with gemcitabine reduced the risk of death - by 26 percent compared to gemcitabine alone (HR=0.74; CI 0.427 - 1.284) .
All told, Pfizer’s Axitinib promises a better value proposition on all counts of efficacy, overall survival and delivery than existing therapies and future therapies must content with the superiority of Axitinib’s results.
SWOT ANALYSIS
Strengths
• Strong marketing and sales capabilities to roll out a successful product pre and post launches.
• Axitinib presents a strong value proposition for gold stand in PC treatment
• Long standing relationships with the medical community
Weakness;
• Pfizer is relatively a new entrant in the cancer space compare with competitors like Genentech and Lilly.
•ggggggggggggggggggggggggggggggggggggggggggg ggggggggggggggg ggggggggg hhhhhhhhhhhhh wss s s s ssssssss s ssssss
Results from a randomized Phase II study of 103 previously untreated patients with advanced pancreatic cancer demonstrated median overall survival with axitinib in combination with gemcitabine of 6.9 months compared with 5.6 months with gemcitabine alone. Axitinib combined with gemcitabine reduced the risk of death - by 26 percent compared to gemcitabine alone (HR=0.74; CI 0.427 - 1.284) .
All told, Pfizer’s Axitinib promises a better value proposition on all counts of efficacy, overall survival and delivery than e ...